Download full-text PDF

Source

Publication Analysis

Top Keywords

teriparatide alendronate
4
alendronate glucocorticoid-induced
4
glucocorticoid-induced osteoporosis
4
teriparatide
1
glucocorticoid-induced
1
osteoporosis
1

Similar Publications

Alendronate, a second-generation bisphosphonate, remains the first-line therapeutic option for postmenopausal osteoporosis. It acts on the bone resorbing osteoclasts causing their apoptosis. This is achieved by producing toxic adenosine triphosphate (ATP) analogues and interfering with the mevalonate pathway.

View Article and Find Full Text PDF
Article Synopsis
  • - The report by the European Calcified Tissue Society (ECTS) outlines evidence-based recommendations for preventing and treating glucocorticoid-induced osteoporosis (GIOP) in adults, aimed at healthcare providers who may not specialize in bone health.
  • - Experts reviewed the literature and created 25 recommendations that categorize patients based on their fracture risk: medium, high, and very high, considering factors like age and history of fractures for appropriate treatment strategy.
  • - Key general measures include optimizing calcium and vitamin D intake, assessing fracture risk regularly for those on glucocorticoids for three months or longer, and minimizing fall risks among patients.
View Article and Find Full Text PDF
Article Synopsis
  • A 64-year-old woman with a long history of bisphosphonate use experienced a displaced atypical femur fracture due to a fall, requiring surgical intervention.
  • The patient underwent a unique surgical technique that involved removing abnormal bone at the fracture site and securing the bone with an intramedullary nail, while also starting teriparatide therapy post-surgery.
  • Her recovery was notably quick, achieving full fracture healing in 3.5 months, which is significantly faster than the average healing time for atypical femur fractures reported at 10.7 months.
View Article and Find Full Text PDF

Unlabelled: Sequential romosozumab-to-alendronate or sequential teriparatide-to-alendronate can be a cost-effective treatment option for postmenopausal women at very high risk of fracture.

Purpose: To estimate the 10-year probability of a major osteoporotic fracture (MOF) at which sequential treatment with romosozumab or teriparatide followed by alendronate, compared with alendronate alone, becomes cost-effective in a UK setting.

Methods: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), in women receiving sequential treatment with either romosozumab or teriparatide followed by alendronate, compared with alendronate alone.

View Article and Find Full Text PDF

Unlabelled: The association of renal function with fracture incidence during teriparatide or alendronate treatment in elderly Japanese women was examined. Fracture incidence differed by fracture type, renal function, and treatment protocol. The results provide important information on pharmacotherapy in clinical practice for osteoporosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!